Insulin-like growth factor I preserves renal function postoperatively

Samuel C. Franklin, Michael Moulton, Gregorio A. Sicard, Marc R. Hammerman, Steven B. Miller

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Deterioration of renal function, which can lead to postoperative renal failure, is a complication of surgery involving the suprarenal aorta and surgery involving the renal arteries. Fifty-four patients who were at risk for developing this complication were enrolled in a double-blind, randomized, placebo-controlled trial of insulin-like growth factor (IGF-I) as a therapeutic agent to prevent the decline in renal function. The primary end point was the incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. IGF-I (100 μg/kg subcutaneously every 12 h for 6 doses) or placebo was administered on admission to the intensive care unit immediately postoperatively. IGF-I- and placebo-treated groups were well matched for sex, age, type of surgery, renal ischemic time during surgery (ischemic index), baseline creatinine clearance, and baseline serum creatinine. No patient in the study developed acute renal failure postoperatively. IGF-I was well tolerated. A smaller proportion of patients in the IGF-I group had a postoperative decline in renal function (22%) than in the placebo-treated group (33%). There were no significant differences in levels of serum creatinine at time of discharge, length of hospital stay, length of intensive care unit stay, length of intubation, or incidence of dialysis or death. Our findings establish the feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction in high-risk patients.

Original languageEnglish (US)
Pages (from-to)F257-F259
JournalAmerican Journal of Physiology - Renal Physiology
Volume272
Issue number2 41-2
StatePublished - Feb 1 1997

Fingerprint

Insulin-Like Growth Factor I
Kidney
Creatinine
Placebos
Length of Stay
Intensive Care Units
Incidence
Renal Artery
Serum
Glomerular Filtration Rate
Acute Kidney Injury
Intubation
Renal Insufficiency
Aorta
Dialysis
Randomized Controlled Trials

Keywords

  • Abdominal aortic aneurysm
  • Glomerular filtration rate
  • Growth factor
  • Renal dysfunction
  • Renal ischemia

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Franklin, S. C., Moulton, M., Sicard, G. A., Hammerman, M. R., & Miller, S. B. (1997). Insulin-like growth factor I preserves renal function postoperatively. American Journal of Physiology - Renal Physiology, 272(2 41-2), F257-F259.

Insulin-like growth factor I preserves renal function postoperatively. / Franklin, Samuel C.; Moulton, Michael; Sicard, Gregorio A.; Hammerman, Marc R.; Miller, Steven B.

In: American Journal of Physiology - Renal Physiology, Vol. 272, No. 2 41-2, 01.02.1997, p. F257-F259.

Research output: Contribution to journalArticle

Franklin, SC, Moulton, M, Sicard, GA, Hammerman, MR & Miller, SB 1997, 'Insulin-like growth factor I preserves renal function postoperatively', American Journal of Physiology - Renal Physiology, vol. 272, no. 2 41-2, pp. F257-F259.
Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller SB. Insulin-like growth factor I preserves renal function postoperatively. American Journal of Physiology - Renal Physiology. 1997 Feb 1;272(2 41-2):F257-F259.
Franklin, Samuel C. ; Moulton, Michael ; Sicard, Gregorio A. ; Hammerman, Marc R. ; Miller, Steven B. / Insulin-like growth factor I preserves renal function postoperatively. In: American Journal of Physiology - Renal Physiology. 1997 ; Vol. 272, No. 2 41-2. pp. F257-F259.
@article{3e9bbfe1fd9d4ca78876a08b31ba1c88,
title = "Insulin-like growth factor I preserves renal function postoperatively",
abstract = "Deterioration of renal function, which can lead to postoperative renal failure, is a complication of surgery involving the suprarenal aorta and surgery involving the renal arteries. Fifty-four patients who were at risk for developing this complication were enrolled in a double-blind, randomized, placebo-controlled trial of insulin-like growth factor (IGF-I) as a therapeutic agent to prevent the decline in renal function. The primary end point was the incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. IGF-I (100 μg/kg subcutaneously every 12 h for 6 doses) or placebo was administered on admission to the intensive care unit immediately postoperatively. IGF-I- and placebo-treated groups were well matched for sex, age, type of surgery, renal ischemic time during surgery (ischemic index), baseline creatinine clearance, and baseline serum creatinine. No patient in the study developed acute renal failure postoperatively. IGF-I was well tolerated. A smaller proportion of patients in the IGF-I group had a postoperative decline in renal function (22{\%}) than in the placebo-treated group (33{\%}). There were no significant differences in levels of serum creatinine at time of discharge, length of hospital stay, length of intensive care unit stay, length of intubation, or incidence of dialysis or death. Our findings establish the feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction in high-risk patients.",
keywords = "Abdominal aortic aneurysm, Glomerular filtration rate, Growth factor, Renal dysfunction, Renal ischemia",
author = "Franklin, {Samuel C.} and Michael Moulton and Sicard, {Gregorio A.} and Hammerman, {Marc R.} and Miller, {Steven B.}",
year = "1997",
month = "2",
day = "1",
language = "English (US)",
volume = "272",
pages = "F257--F259",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "2 41-2",

}

TY - JOUR

T1 - Insulin-like growth factor I preserves renal function postoperatively

AU - Franklin, Samuel C.

AU - Moulton, Michael

AU - Sicard, Gregorio A.

AU - Hammerman, Marc R.

AU - Miller, Steven B.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - Deterioration of renal function, which can lead to postoperative renal failure, is a complication of surgery involving the suprarenal aorta and surgery involving the renal arteries. Fifty-four patients who were at risk for developing this complication were enrolled in a double-blind, randomized, placebo-controlled trial of insulin-like growth factor (IGF-I) as a therapeutic agent to prevent the decline in renal function. The primary end point was the incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. IGF-I (100 μg/kg subcutaneously every 12 h for 6 doses) or placebo was administered on admission to the intensive care unit immediately postoperatively. IGF-I- and placebo-treated groups were well matched for sex, age, type of surgery, renal ischemic time during surgery (ischemic index), baseline creatinine clearance, and baseline serum creatinine. No patient in the study developed acute renal failure postoperatively. IGF-I was well tolerated. A smaller proportion of patients in the IGF-I group had a postoperative decline in renal function (22%) than in the placebo-treated group (33%). There were no significant differences in levels of serum creatinine at time of discharge, length of hospital stay, length of intensive care unit stay, length of intubation, or incidence of dialysis or death. Our findings establish the feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction in high-risk patients.

AB - Deterioration of renal function, which can lead to postoperative renal failure, is a complication of surgery involving the suprarenal aorta and surgery involving the renal arteries. Fifty-four patients who were at risk for developing this complication were enrolled in a double-blind, randomized, placebo-controlled trial of insulin-like growth factor (IGF-I) as a therapeutic agent to prevent the decline in renal function. The primary end point was the incidence of renal dysfunction, defined as a reduction of the glomerular filtration rate (creatinine clearance) at each of three measurements over 72 h. IGF-I (100 μg/kg subcutaneously every 12 h for 6 doses) or placebo was administered on admission to the intensive care unit immediately postoperatively. IGF-I- and placebo-treated groups were well matched for sex, age, type of surgery, renal ischemic time during surgery (ischemic index), baseline creatinine clearance, and baseline serum creatinine. No patient in the study developed acute renal failure postoperatively. IGF-I was well tolerated. A smaller proportion of patients in the IGF-I group had a postoperative decline in renal function (22%) than in the placebo-treated group (33%). There were no significant differences in levels of serum creatinine at time of discharge, length of hospital stay, length of intensive care unit stay, length of intubation, or incidence of dialysis or death. Our findings establish the feasibility and potential utility for the use of IGF-I to reduce the incidence of postoperative renal dysfunction in high-risk patients.

KW - Abdominal aortic aneurysm

KW - Glomerular filtration rate

KW - Growth factor

KW - Renal dysfunction

KW - Renal ischemia

UR - http://www.scopus.com/inward/record.url?scp=0030764263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030764263&partnerID=8YFLogxK

M3 - Article

C2 - 9124404

AN - SCOPUS:0030764263

VL - 272

SP - F257-F259

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 2 41-2

ER -